林清轩冲刺港股IPO，有望成国货高端护肤领军者

Group 1 - Lin Qingxuan Biotech Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on May 29, aiming for a main board listing, potentially becoming the "first high-end domestic skincare stock" in Hong Kong [2] - Founded in 2003, the company specializes in anti-wrinkle and firming skincare products, featuring natural camellia flower ingredients, and has sold over 30 million bottles of its core product, camellia anti-wrinkle repair essence oil, since its launch in 2014 [2] - Financial data shows revenue growth from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with a compound annual growth rate of 32.3%, and net profit turning from a loss of 5.93 million yuan in 2022 to a profit of 187 million yuan in 2024 [2] Group 2 - The company operates 506 stores nationwide, with over 95% located in shopping malls, leading in store count among domestic and international high-end skincare brands [2] - Online sales are strong, with the company topping multiple essence oil sales rankings on Tmall in 2024, accumulating over 4.3 million active customers and an average annual repurchase rate of 34.6% [2] - The funds raised from the IPO will be primarily used for brand building, channel expansion, supply chain enhancement, technology research and development, brand matrix creation, and digitalization [3]